Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:33:48 EDT Thu 03 Jul 2025
Enter Symbol
or Name
USA
CA



Q:VTRS - VIATRIS INC - https://www.viatris.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VTRS - Q2.69.20·9.500.59.32-0.02-0.26,343.958,23713,5759.33  9.37  9.2213.55  6.8516:33:45Jun 2615 min RT 2¢

Recent Trades - Last 10 of 13575
Time ETExPriceChangeVolume
16:33:45Q9.350.0111
16:20:00Q9.32-0.021,058
15:59:56Q9.26-0.0813
15:33:11Q9.22-0.121
14:51:35Q9.34960.0096500
14:22:42Q9.350.013
14:21:38Q9.22-0.121
13:48:14Q9.21-0.1376
13:33:03Q9.350.013
13:24:10Q9.32-0.021

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-26 06:55U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Second Pivotal Phase 3 VEGA-3 Trial of MR-141 in Presbyopia
2025-06-12 16:30U:VTRSNews ReleaseViatris to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-06-02 08:00U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Phase 3 LYNX-2 Trial of MR-142 in Keratorefractive Patients With Visual Disturbances Under Mesopic, Low-Contrast Conditions
2025-05-27 06:59U:VTRSNews ReleaseViatris Announces Launch of First Clozapine Orally Disintegrating Tablet (ODT) in Canada
2025-05-22 06:59U:VTRSNews ReleaseViatris to Participate in Upcoming Investor Conferences
2025-05-08 06:59U:VTRSNews ReleaseViatris Reports First Quarter 2025 Results and Reaffirms 2025 Outlook
2025-05-08 06:45U:VTRSNews ReleaseViatris Announces Positive Results from Phase 3 Study of Investigational XULANE LO(TM) Low Dose Patch for Birth Control in Women of Childbearing Potential
2025-05-08 06:30U:VTRSNews ReleaseViatris Announces Positive Top-Line Results from Two Pivotal Phase 3 Studies of Novel Fast-Acting Meloxicam (MR-107A-02) for the Treatment of Moderate-to-Severe Acute Pain
2025-05-07 06:59U:VTRSNews ReleaseViatris Announces Quarterly Dividend
2025-05-05 16:30U:VTRSNews ReleaseViatris Announces Appointments of Frank D'Amelio and Michael Severino, M.D., to the Company's Board of Directors
2025-04-25 06:59U:VTRSNews ReleaseViatris to Present at the BofA Securities 2025 Healthcare Conference
2025-04-21 06:59U:VTRSNews ReleaseViatris Files Supplemental New Drug Applications to Japan's Ministry of Health, Labor and Welfare for the Approval of EFFEXOR(TM) for the Treatment of Generalized Anxiety Disorder
2025-04-14 06:59U:VTRSNews ReleaseViatris Appoints Hemanth J. Varghese as Chief Strategy Officer
2025-04-07 06:59U:VTRSNews ReleaseViatris Statement on Nationwide Settlement to Resolve Opioid-Related Claims
2025-03-28 06:59U:VTRSNews ReleaseViatris to Report First Quarter 2025 Financial Results on May 8, 2025
2025-03-05 16:30U:VTRSNews ReleaseViatris to Present at the Barclays 27th Annual Global Healthcare Conference
2025-02-27 06:45U:VTRSNews ReleaseViatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance
2025-02-27 06:30U:VTRSNews ReleaseViatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend
2025-02-19 10:49U:VTRSNews ReleaseUniting Against AMR: Global Solutions Need Local and Global Collaboration
2025-02-17 17:00U:VTRSNews Release50 Years of Service: From Milkman's Son to Advancing Access to Medicines